Archive · 24 Jun 2025
Biocon Biologics Partners for Affordable Cancer Treatment in Malaysia
Imagine a company called Biocon Biologics that makes affordable medicine for serious illnesses.
They teamed up with a group in Malaysia that helps people with cancer.
Together, they're starting a program to help cancer patients who can't afford their treatments.
Biocon will provide important cancer medicines, and the Malaysian group will help patients get them.
The first medicine offered will be Trastuzumab, helping those who are struggling financially.
This partnership aims to make it easier for people to get the cancer care they need.
Biocon Biologics partnered with the National Cancer Society of Malaysia to make cancer treatment more affordable.
The Patient Assistance Program (PAP) will supply key oncology biosimilars like Trastuzumab, Pegfilgrastim, and Bevacizumab.
NCSM will handle patient enrollment and medicine distribution for the program.
The program will initially offer Trastuzumab to patients facing financial constraints.
The partnership was formalized during the National Cancer Congress Malaysia 2025 in Kuala Lumpur.
- Who
- Biocon Biologics and the National Cancer Society of Malaysia (NCSM).
- What
- Biocon Biologics and NCSM partnered to launch a Patient Assistance Program for affordable cancer treatment.
- When
- The partnership was formalized at the National Cancer Congress Malaysia 2025.
- Where
- Malaysia, specifically Kuala Lumpur for the Congress.
- Why
- To make cancer treatment more affordable and accessible for underserved patients.
- Company
- Biocon Biologics
- Partner
- National Cancer Society of Malaysia (NCSM)
- Program
- Patient Assistance Program (PAP)
- Focus
- Affordable cancer treatment
- Key Drugs
- Trastuzumab, Pegfilgrastim, Bevacizumab
- Location of Congress
- Kuala Lumpur
- Biosimilars
- The company develops and delivers affordable biosimilars